Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ATP4A | P20648 | 2/20 | 0.33 |
| ▸ | ATP4B | P51164 | 2/20 | 0.33 |
| ▸ | ALAD | P13716 | 2/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560661 | 0.81 | ESR2 (0.47) | ALDH1A1MEN1MAPTKMT2AESR2 | |
| SCHEMBL2556986 | 0.81 | CA2 (0.40) | ALDH1A1GAAMAPTKMT2AORAI1 | |
| SCHEMBL290331 | 0.80 | MGLL (0.45) | ALDH1A1MAPTBCL2L1ALOX5RAB9A | |
| SCHEMBL2558010 | 0.77 | NPC1 (0.46) | ALDH1A1MAPTRAB9AESR2KDM4E | |
| SCHEMBL29952286 | 0.74 | — | — | |
| SCHEMBL28617847 | 0.73 | CYP2A6 (0.42) | — | |
| SCHEMBL2559750 | 0.73 | ESR1 (0.39) | ALDH1A1GAAMAPTRAB9AESR2 | |
| SCHEMBL28225284 | 0.71 | HSD17B1 (0.52) | ALDH1A1MEN1GAAMAPTKMT2A | |
| SCHEMBL12466215 | 0.69 | ALDH1A1 (0.47) | ALDH1A1MEN1GAAMAPTKMT2A | |
| SCHEMBL2556636 | 0.69 | ATP4A (0.39) | ALDH1A1MEN1MAPTKMT2AATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4298098-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2024-01-03 | — | — | EP | disclosed |
| CN-114835704-B | Sulfonylbenzamide derivatives as BCL-2 inhibitors | 苏州亚盛药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022161496-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-08-04 | — | — | WO | disclosed |
| CN-114835704-A | Sulfonylbenzamide derivatives as BCL-2 inhibitors | 苏州亚盛药业有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577245-B2 | Sulfonyl benzamide derivatives as Bcl-2 inhibitors | BCL2A1, BCL2L1, BCL2L11 | ALDH1A1 1756/4885MEN1 4514/4885GAA 1969/4885 |
| US-20240166644-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | ALDH1A1 2264/4885MEN1 2936/4885GAA 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.